Works matching IS 11727047 AND DT 2025 AND VI 39 AND IP 3

Results: 9

Post-marketing Experience with Cenobamate in the Treatment of Focal Epilepsies: A Multicentre Cohort Study: CNB in Focal Epilepsies: A. Strzelczyk et al.

Published in:

CNS Drugs, 2025, v. 39, n. 3, p. 321, doi. 10.1007/s40263-025-01158-8

By:

Strzelczyk, Adam;
von Podewils, Felix;
Hamer, Hajo M.;
Knake, Susanne;
Rosenow, Felix;
Klotz, Kerstin Alexandra;
Kurlemann, Gerhard;
Melzer, Nico;
Buhleier, Elisa;
Mann, Catrin;
Willems, Laurent M.;
Zöllner, Johann Philipp;
Gaida, Bernadette;
Cuny, Jeanne;
Bellaire, David;
Immisch, Ilka;
Kämppi, Leena;
Brunklaus, Andreas;
Schubert-Bast, Susanne

Publication type:

Article

Comment on: "A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal‑Onset Epilepsy": A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment: Z. Liu et al

Published in:

2025

By:

Liu, Zhongxing;
Tian, Mengzhe;
Duan, Lincheng

Publication type:

Letter

Author's Reply to Liu et al.: "A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal‑Onset Epilepsy": Author's Reply to Liu et al.: M. Hirsch.

Published in:

2025

By:

Hirsch, Martin

Publication type:

Letter

Targeting Kv7 Potassium Channels for Epilepsy: Kv7-Targeting for Epilepsy: E. Perucca, M. Taglialatela.

Published in:

CNS Drugs, 2025, v. 39, n. 3, p. 263, doi. 10.1007/s40263-024-01155-3

By:

Perucca, Emilio;
Taglialatela, Maurizio

Publication type:

Article

Raynaud Syndrome Associated with Medication for Attention-Deficit/Hyperactivity Disorder: A Systematic Review: Raynaud Syndrome Associated with Medication for ADHD: F. M. C. Besag et al.

Published in:

CNS Drugs, 2025, v. 39, n. 3, p. 213, doi. 10.1007/s40263-024-01154-4

By:

Besag, Frank M. C.;
Vasey, Michael J.;
Roy, Sulagna;
Cortese, Samuele

Publication type:

Article

Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach: Anti-EBV Drugs for MS: V. Li et al.

Published in:

CNS Drugs, 2025, v. 39, n. 3, p. 305, doi. 10.1007/s40263-024-01153-5

By:

Li, Vivien;
McKay, Fiona C.;
Tscharke, David C.;
Smith, Corey;
Khanna, Rajiv;
Lechner-Scott, Jeannette;
Rawlinson, William D.;
Lloyd, Andrew R.;
Taylor, Bruce V.;
Morahan, Julia M.;
Steinman, Lawrence;
Giovannoni, Gavin;
Bar-Or, Amit;
Levy, Michael;
Drosu, Natalia;
Potter, Andrew;
Caswell, Nigel;
Smith, Lynne;
Brady, Erin C.;
Frost, Bruce

Publication type:

Article

Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape: Treatment of Negative Symptoms of Schizophrenia: P. Govil, J. T. Kantrowitz.

Published in:

CNS Drugs, 2025, v. 39, n. 3, p. 243, doi. 10.1007/s40263-024-01151-7

By:

Govil, Preetika;
Kantrowitz, Joshua T.

Publication type:

Article

Correction: Comment on "Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population": Correction: Comment on "Effectiveness of Anti-Calcitonin Gene-Related Peptide...: X. Zhou et al

Published in:

2025

By:

Zhou, Xin;
Zhang, Aiping;
Lin, Riyang

Publication type:

Correction Notice

Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy, Safety and Tolerability of Modified-Release Methylphenidate (MPH-MR) in Chinese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): MPH-MR in Chinese Children and Adolescents with ADHD: Y. Zheng et al

Published in:

CNS Drugs, 2025, v. 39, n. 3, p. 289, doi. 10.1007/s40263-024-01136-6

By:

Zheng, Yi;
Liu, Huaqing;
Wang, Xiuxia;
Li, Haibo;
Ruhmann, Michaela;
Mayer, Anke;
Dangel, Oliver;
Ammer, Richard

Publication type:

Article